Henderson Molly

Average Profitability
<0.0001%
Insider Buys Quantity
2
Insider Buys Sum
$79,250.00
Insider Sells Quantity
12
Insider Sells Sum
$410,216.99

Insider Activity of Henderson Molly

According to the SEC Form 4 filings, Henderson Molly, being in a position of

  1. CFO and CBO at Phathom Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 16194 shares for $153,120,
    over all time since 2022-05-13, has bought 6000 shares for $0, and sold 40386 shares for $376,586.

The largest purchase of all time was on 2021-05-17 and amounted to 5000 shares of UroGen Pharma Ltd. for $79,250.

The largest sale of all time was on 2023-11-01 and amounted to 12492 shares of Phathom Pharmaceuticals, Inc. for $110,871.

Biography of Henderson Molly

No biography is available at this moment.

2024-07-15SalePhathom Pharmaceuticals, Inc.
PHAT
CFO and CBO
4,325
0.0085%
$11.72$50,6890%
2024-04-08SalePhathom Pharmaceuticals, Inc.
PHAT
CFO and CBO
3,435
0.0059%
$11.10$38,129+3.6%
2024-01-19SalePhathom Pharmaceuticals, Inc.
PHAT
CFO and CBO
6,307
0.0114%
$7.75$48,900+42.91%
2023-11-20SalePhathom Pharmaceuticals, Inc.
PHAT
CFO and CBO
2,127
0.0037%
$7.24$15,403+37.99%
2023-11-01SalePhathom Pharmaceuticals, Inc.
PHAT
CFO and CBO
12,492
0.0202%
$8.88$110,871+5.52%
2023-06-02SalePhathom Pharmaceuticals, Inc.
PHAT
CFO and CBO
1,960
0.0045%
$11.41$22,368-13.46%
2023-05-22SalePhathom Pharmaceuticals, Inc.
PHAT
CFO and CBO
2,110
0.0048%
$12.87$27,165-24.78%
2023-04-06SalePhathom Pharmaceuticals, Inc.
PHAT
CFO and CBO
3,439
0.0079%
$7.27$25,002+34.68%
2023-03-01SalePhathom Pharmaceuticals, Inc.
PHAT
CFO and CBO
2,032
0.0047%
$8.53$17,335+13.21%
2022-11-21SalePhathom Pharmaceuticals, Inc.
PHAT
CFO and CBO
2,159
0.0054%
$9.60$20,726+9.39%
2022-05-13PurchasePhathom Pharmaceuticals, Inc.
PHAT
CFO and CBO
6,000
$0$0+21.9%
2022-01-31SaleUroGen Pharma Ltd.
URGN
Chief Financial Officer
331
0.0014%
$7.58$2,509+5.96%
2021-11-30SaleUroGen Pharma Ltd.
URGN
Chief Financial Officer
2,587
0.0115%
$12.03$31,122-31.97%
2021-05-17PurchaseUroGen Pharma Ltd.
URGN
Chief Financial Officer
5,000
0.0222%
$15.85$79,250-10.34%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.